A month has gone by since the last earnings report for Apellis Pharmaceuticals, Inc. (APLS) . Shares have added about 7.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Apellis Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been ...

Company Overview - Beam Therapeutics Inc. (BEAM) shares have increased by approximately 5.7% over the past month, which is underperforming compared to the S&P 500 [1] - The most recent earnings report is essential for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Beam Therapeutics have remained flat over the past month, indicating no significant changes in expectations [2] VGM Scores - Beam Therapeutics has a poor Growth Score of F and a Momentum Score of C, while its Value Score is also rated F, placing it in the lowest quintile for this investment strategy [3] - The overall aggregate VGM Score for Beam Therapeutics is F, which is a critical score for investors not focused on a single strategy [3] Outlook - Beam Therapeutics holds a Zacks Rank of 3 (Hold), suggesting an expectation of an in-line return from the stock in the upcoming months [4] Industry Comparison - Beam Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Bristol Myers Squibb (BMY) has seen a 0.7% increase in shares over the past month [5] - Bristol Myers reported revenues of $11.2 billion for the last quarter, reflecting a year-over-year decline of 5.6%, with an EPS of $1.80 compared to -$4.40 a year ago [5] - For the current quarter, Bristol Myers is expected to post earnings of $1.67 per share, representing a year-over-year change of -19.3% [6] - The Zacks Consensus Estimate for Bristol Myers has changed by +0.1% over the last 30 days, maintaining a Zacks Rank of 3 (Hold) and a VGM Score of A [6]

Company Overview - CRISPR Therapeutics AG (CRSP) shares have increased by approximately 11.1% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is essential for understanding the key drivers behind this performance [1] Earnings Estimates - Estimates for CRISPR Therapeutics have trended downward over the past month, with a consensus estimate shift of -20.48% [2] - The stock currently holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [4] VGM Scores - CRISPR Therapeutics has an average Growth Score of C and a Momentum Score of B, but a low Value Score of F, placing it in the bottom 20% for this investment strategy [3] - The overall aggregate VGM Score for the stock is D, which is relevant for investors not focused on a single strategy [3] Industry Performance - CRISPR Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Exact Sciences (EXAS) has gained 3.6% over the past month [5] - Exact Sciences reported revenues of $706.78 million for the last quarter, reflecting a year-over-year increase of +10.9% [5] - The expected loss for Exact Sciences in the current quarter is $0.08 per share, with a year-over-year change of +11.1% [6]

It has been about a month since the last earnings report for Krystal Biotech, Inc. (KRYS) . Shares have lost about 3.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Krystal Biotech due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving ...

Group 1 - Myriad Genetics (MYGN) shares have increased by approximately 23.9% over the past month, outperforming the S&P 500 [1] - Recent estimates for Myriad have trended downward, with a consensus estimate shift of -5.56% [2] - Myriad has a Growth Score of A, a Momentum Score of F, and a Value Score of C, resulting in an aggregate VGM Score of C [3] Group 2 - The overall outlook for Myriad indicates a downward shift in estimates, with a Zacks Rank of 3 (Hold), suggesting an in-line return expected in the coming months [4] - Myriad is part of the Zacks Medical - Biomedical and Genetics industry, where GSK has gained 9.8% over the past month [5] - GSK reported revenues of $9.46 billion for the last quarter, reflecting a year-over-year increase of +1.4% [5]

生物制造是以生物体机能进行大规模物质加工与物质转化、为社会发展提供工业商品的新行业，是 发展新质生产力和战略性新兴产业的重要方向。湖北要在推进科技创新和产业创新方面开拓进取，坚持 传统产业转型升级与培育壮大新兴产业、未来产业齐头并进。 作为生物产业大省，湖北发展生物制造有基础、有条件、有路径，应立足省情努力打造生物制造创 新高地。湖北大学作为地方高校，更应抢抓机遇、固本培新，为湖北生物产业开拓新的效益增长点，助 力地方传统产业实现绿色转型。 塑造产业高地 近年来，生物学领域的技术突破，推动该学科出现跃迁式发展，促进研究成果从实验室走向应用与 产业。 湖北高校生物学及相关学科实力强劲，为生物科技及基础人才的储备提供了坚实保障。武汉光谷生 物城重点围绕生物医药、生物医学工程、生物农业、生物服务等领域，已聚集生物企业8259家，拥有核 心专利10847个，大部分专利来自科研院所的实验室。湖北现有生物医药企业11.5万家，生物医药专利 数量3.6452万个，其中武汉市生物医药企业4.208万家，生物医药专利数量1.9791万个。 湖北着力打造的五个万亿级产业中，大健康、现代农产品加工等产业与生物制造深度相关。生物制 ...

每经记者｜王海慜 每经编辑｜叶峰 最近，国内玻尿酸行业龙头华熙生物通过官方微信公众号发布约5000字长文《概念总在重演，科技永远向前》，矛头直指9家券商的10篇研究报告存在"误导 性言论"。 此事件持续发酵的背后牵扯多个疑点。经查询多个主流证券资讯平台发现，目前这10篇研报中仅有西部证券的《科技为舟，引领胶原蛋白健康美学》无法检 索到。就相关研报的去向，记者今日向西部证券方面进行了求证。 此外，记者通读此次被华熙生物指出的多篇"问题研报"发现，对于玻尿酸和重组胶原蛋白的优劣判断，华泰证券等券商研报有一定倾向性，申港证券的研报 还存在前后矛盾之处。 不过，相比之下，其他多篇研报在胶原蛋白和玻尿酸的站队中并没有选择"一边倒"。那么，既然如此，为何至今没有任何券商对此公开进行回应？这几天， 此事件在分析师群体中也引发热议。 西部证券疑似已删除研报 近几年，科创板医美龙头华熙生物面临业绩和市值双重缩水的压力。最近，公司打破沉默，用一篇檄文揭开自身困境的部分诱因。 5月17日，华熙生物通过官方微信公众号发布近5000字长文《概念总在重演，科技永远向前》，矛头直指9家券商的10篇研究报告存在误导性言论，声称，近 年来"为 ...

方舟投资创始人伍德认为，特朗普的关税政策本质是为了减少贸易壁垒，这对股市来说是积极信号。她 上周在美中经贸关系缓和之际增持了中国科技股。 木头姐;、方舟投资（ARK Invest）创始人凯西・伍德（Cathie Wood）认为，在经历美国总统特朗普4月 关税政策引发的波动后，股市可能迎来转折点。 她周一在采访中表示，投资者开始意识到国际贸易谈判可能导向解放市场;。伍德称，她认为白宫的策 略本质是减少贸易壁垒：若最终达成这一目标，相当于减税，是积极信号。;谈及本月美英达成的贸易 协议，伍德表示希望更多协议能落地，成为美国开放市场的双向通道;。 伍德在2020年斩获153%的惊人收益，借此树立声誉并吸引了忠实跟随者。但她的长期表现令许多人对 其激进风格存疑。截至5月16日，管理规模50亿美元的ARK创新ETF五年年化回报率仅为0.59%，同期标 普500年化回报率为17.57%。 当被问及美国预算赤字膨胀问题时，伍德称相信随着技术创新加速，美国能够通过增长摆脱赤字;。其 投资基金以押注颠覆性技术闻名的伍德重申，医疗保健行业是最被低估;的人工智能（AI）应用受益 者，新工具正加速药物发现与开发。 伍德以支持AI和机 ...

"有了这色彩斑斓的薄膜，它可就不是普通的玻璃基片了，而是精密医学诊断设备里的核心'武 器'！"5月13日，在辽宁省企业产品和技术创新成果展"专精特新"展区，沈阳仪表科学研究院有限公司 光学技术负责人王瑞生手持展品进行介绍。 这款生物医学精密光学滤光片，是企业斩获的国家制造业单项冠军产品。该产品应用离我们的生活 也不遥远，体检时的血液化验单，上面的"荧光检测法"就是通过这款产品实现的。"薄膜起到了'闸门'的 作用，它们根据检测需求，只允许特定波长的光通过，从而准确捕捉检测物中各类标志物的荧光信号， 提供诊断依据。"王瑞生介绍，公司自主创新突破膜系技术等多项难题，研发的精密薄膜镀制与膜厚控 制技术，能实现200至300层薄膜产品的精密沉积制造。 沿展区继续向前，这些澎湃"新"潮的技术和产品亦让人心潮澎湃。 以专注铸专长、精益出效益、特色赢市场、创新谋发展，"专精特新"企业作为强链补链延链的生力 军，其研发的新产品、新技术、新工艺也为战略性新兴产业发展注入强劲动能。目前，我省已有4个集 群获评国家先进制造业产业集群。 在近旁的战略性新兴产业展区，一批高端前沿的创新成果，直观展现我省科技创新和产业创新深度 融合的良好 ...

Core Viewpoint - Dare Bioscience, Inc. reported a quarterly loss of $0.50 per share, which was better than the Zacks Consensus Estimate of a loss of $0.63, indicating an earnings surprise of 20.63% [1] Financial Performance - The company posted revenues of $0.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 95.83%, compared to revenues of $0.01 million a year ago [2] - Over the last four quarters, the company has surpassed consensus EPS estimates four times but has not been able to beat consensus revenue estimates [2] Stock Performance - Dare Bioscience shares have lost about 7.7% since the beginning of the year, while the S&P 500 has declined by 0.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.43 on $0.6 million in revenues, and for the current fiscal year, it is -$1.97 on $3.3 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Dare Bioscience belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]